Drugs / R306465
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00677001 | Sep 2005 → Oct 2006 | neoplasm | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R306465 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00677001 ↗ |
| Known as | JNJ-16241199 | ChEMBL registry synonym — accepted as the source's own label CHEMBL609583 ↗ |
| Action | Inhibit | “histone deacetylase (HDAC) inhibitor” NCT00677001 ↗ |
| Modality | Small molecule | — CHEMBL609583 ↗ |
| Route | Oral | “R306465 will be administered orally once daily” NCT00677001 ↗ |